Log in or register to see all Alerts
New HTA Decisions in France
December 2019
Drug name
ORENCIA® (abatacept)
Company
Bristol-Myers Squibb
Decision date
02/10/2019
Therapeutic area
Musculoskeletal conditions
Therapeutic sub area
Arthritis
Official notice date
04/11/2019
Reimbursement %
65
Decision (SMR)
Important
Decision (ASMR)
No improvement (V)
Indication
ORENCIA® is indicated for the treatment of moderate to severe active polyarticular juvenile idiopathic arthritis in patients 2 years of age (50 mg, 87.5 mg, 125 mg) or 6 years (250 mg) after previous treatment with a disease-modifying anti-rheumatic drug (DMARD), alone or in combination with methotrexate (MTX).
Decision Type
New technology assessment
Summary
The committee considered the actual benefit of ORENCIA® to be 'important' in the indication of the Marketing Authorisation. It was concluded that ORENCIA® does not provide any improvement in the medical service rendered (ASMR V). The committee proposed 65% reimbursement.